IQVIA Holdings Inc. $IQV Position Reduced by Korea Investment CORP

Korea Investment CORP trimmed its position in IQVIA Holdings Inc. (NYSE:IQV) by 18.7% in the 3rd quarter, HoldingsChannel.com reports. The institutional investor owned 139,914 shares of the medical research company’s stock after selling 32,095 shares during the period. Korea Investment CORP’s holdings in IQVIA were worth $26,575,000 at the end of the most recent quarter.

A number of other large investors have also made changes to their positions in IQV. Rhenman & Partners Asset Management AB lifted its position in shares of IQVIA by 50.0% in the 3rd quarter. Rhenman & Partners Asset Management AB now owns 19,500 shares of the medical research company’s stock valued at $3,704,000 after acquiring an additional 6,500 shares in the last quarter. Angeles Wealth Management LLC purchased a new position in IQVIA during the 3rd quarter worth approximately $215,000. Blair William & Co. IL raised its stake in IQVIA by 7.6% during the 3rd quarter. Blair William & Co. IL now owns 7,151 shares of the medical research company’s stock valued at $1,358,000 after purchasing an additional 502 shares during the period. First Trust Advisors LP lifted its holdings in shares of IQVIA by 22.2% in the third quarter. First Trust Advisors LP now owns 112,426 shares of the medical research company’s stock valued at $21,354,000 after purchasing an additional 20,411 shares in the last quarter. Finally, Neo Ivy Capital Management boosted its position in shares of IQVIA by 1,065.5% in the third quarter. Neo Ivy Capital Management now owns 12,436 shares of the medical research company’s stock worth $2,362,000 after buying an additional 11,369 shares during the period. Institutional investors and hedge funds own 89.62% of the company’s stock.

IQVIA Stock Performance

Shares of NYSE IQV opened at $178.87 on Tuesday. The company has a debt-to-equity ratio of 2.09, a current ratio of 0.75 and a quick ratio of 0.75. IQVIA Holdings Inc. has a one year low of $134.65 and a one year high of $247.04. The business’s 50-day moving average price is $206.26 and its two-hundred day moving average price is $207.53. The company has a market capitalization of $30.35 billion, a P/E ratio of 22.76, a price-to-earnings-growth ratio of 1.68 and a beta of 1.40.

IQVIA (NYSE:IQV) last posted its quarterly earnings results on Thursday, February 5th. The medical research company reported $3.42 earnings per share for the quarter, topping analysts’ consensus estimates of $3.40 by $0.02. The company had revenue of $4.36 billion during the quarter, compared to the consensus estimate of $4.24 billion. IQVIA had a return on equity of 30.50% and a net margin of 8.34%.The business’s quarterly revenue was up 10.3% on a year-over-year basis. During the same period last year, the business earned $3.12 EPS. IQVIA has set its FY 2026 guidance at 12.550-12.850 EPS. Analysts anticipate that IQVIA Holdings Inc. will post 10.84 earnings per share for the current fiscal year.

Analysts Set New Price Targets

IQV has been the topic of several recent analyst reports. Truist Financial dropped their price target on IQVIA from $290.00 to $245.00 and set a “buy” rating on the stock in a research report on Thursday, February 19th. Royal Bank Of Canada initiated coverage on IQVIA in a research report on Tuesday, March 3rd. They set an “outperform” rating and a $221.00 price objective for the company. Jefferies Financial Group dropped their target price on IQVIA from $270.00 to $255.00 and set a “buy” rating on the stock in a report on Friday, February 6th. TD Cowen raised shares of IQVIA from a “hold” rating to a “buy” rating and increased their price target for the stock from $174.00 to $213.00 in a research report on Monday. Finally, Citigroup lowered their price objective on shares of IQVIA from $230.00 to $200.00 and set a “neutral” rating on the stock in a research report on Friday, February 6th. Two equities research analysts have rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and two have given a Hold rating to the company. Based on data from MarketBeat.com, IQVIA has a consensus rating of “Buy” and an average price target of $229.13.

About IQVIA

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.